معرفی
Professor Tillman U. Gerngross is a faculty member at the Thayer School of Engineering at Dartmouth College, where he holds the rank of Professor of Engineering. His research focuses on protein engineering, glycoprotein engineering, and metabolic engineering, with significant contributions to yeast-based production systems for therapeutic proteins. He has pioneered technologies for humanizing glycosylation pathways in yeast, enabling the production of complex glycoproteins for biomedical applications.
Education: BS/MS in Chemical Engineering (1989) and PhD in Molecular Biology (1991), both from the Technical University of Vienna, Austria.
Research Interests: Professor Gerngross’s work bridges biotechnology and engineering, emphasizing scalable production methods for biologics. His lab has developed novel fermentation and protein expression systems, with applications in antibody engineering and metabolic pathway optimization.
Awards: Member of the National Academy of Engineering (2017), 2013 National Academy of Inventors Fellow, and recipient of the 2020 Dartmouth Entrepreneurs Forum Technology Innovation Award.
Entrepreneurial Ventures: Co-founder of multiple biotech companies, including GlycoFi (acquired by Merck for $400M), Adimab, Alector, Avitide (acquired by Repligen), and Adagio Therapeutics. These ventures focus on antibody discovery, cancer therapeutics, and pandemic response technologies.
Grants & Funding: His startups have secured substantial funding through venture capital and strategic partnerships, reflecting their commercial viability and scientific impact. Notable milestones include Avitide’s $150M acquisition and Alector’s $2.2B valuation post-IPO.
Labs & Teams: Leads a multidisciplinary research group at Thayer, collaborating with industry partners to translate academic discoveries into industrial applications. His companies employ advanced R&D teams to develop therapies and biomanufacturing solutions.
